Clinical management of aplastic anemia

Research output: Contribution to journalArticle

Abstract

Acquired aplastic anemia is a potentially fatal bone marrow failure disorder that is characterized by pancytopenia and a hypocellular bone marrow. Hematopoietic stem-cell transplantation or bone marrow transplantation (BMT) is the treatment of choice for young patients who have a matched sibling donor. Immunosuppression with either anti-thymocyte globulin and cyclosporine or high-dose cyclophosphamide is an effective therapy for patients who are not suitable BMT candidates owing to age or lack of a suitable donor. Results of BMT from unrelated and mismatched donors are improving, but presently this treatment option is best reserved for those patients who do not respond, relapse or develop secondary clonal disorders following immunosuppressive therapy. Efforts are currently underway to both improve immunosuppressive regimens and to expand the application of BMT.

Original languageEnglish (US)
Pages (from-to)221-230
Number of pages10
JournalExpert Review of Hematology
Volume4
Issue number2
DOIs
StatePublished - Apr 2011

Fingerprint

Aplastic Anemia
Bone Marrow Transplantation
Immunosuppressive Agents
Bone Marrow
Tissue Donors
Unrelated Donors
Pancytopenia
Antilymphocyte Serum
Hematopoietic Stem Cell Transplantation
Therapeutics
Cyclophosphamide
Immunosuppression
Cyclosporine
Siblings
Recurrence

Keywords

  • anti-thymocyte globulin
  • aplastic anemia
  • bone marrow failure
  • bone marrow transplantation
  • cyclosporine
  • hematopoietic stem-cell transplantation
  • high-dose cyclophosphamide
  • paroxysmal nocturnal hemoglobinuria

ASJC Scopus subject areas

  • Hematology

Cite this

Clinical management of aplastic anemia. / Dezern, Amy; Brodsky, Robert A.

In: Expert Review of Hematology, Vol. 4, No. 2, 04.2011, p. 221-230.

Research output: Contribution to journalArticle

@article{d0043f0d7d68433b94a89448a46bb9ac,
title = "Clinical management of aplastic anemia",
abstract = "Acquired aplastic anemia is a potentially fatal bone marrow failure disorder that is characterized by pancytopenia and a hypocellular bone marrow. Hematopoietic stem-cell transplantation or bone marrow transplantation (BMT) is the treatment of choice for young patients who have a matched sibling donor. Immunosuppression with either anti-thymocyte globulin and cyclosporine or high-dose cyclophosphamide is an effective therapy for patients who are not suitable BMT candidates owing to age or lack of a suitable donor. Results of BMT from unrelated and mismatched donors are improving, but presently this treatment option is best reserved for those patients who do not respond, relapse or develop secondary clonal disorders following immunosuppressive therapy. Efforts are currently underway to both improve immunosuppressive regimens and to expand the application of BMT.",
keywords = "anti-thymocyte globulin, aplastic anemia, bone marrow failure, bone marrow transplantation, cyclosporine, hematopoietic stem-cell transplantation, high-dose cyclophosphamide, paroxysmal nocturnal hemoglobinuria",
author = "Amy Dezern and Brodsky, {Robert A}",
year = "2011",
month = "4",
doi = "10.1586/ehm.11.11",
language = "English (US)",
volume = "4",
pages = "221--230",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Clinical management of aplastic anemia

AU - Dezern, Amy

AU - Brodsky, Robert A

PY - 2011/4

Y1 - 2011/4

N2 - Acquired aplastic anemia is a potentially fatal bone marrow failure disorder that is characterized by pancytopenia and a hypocellular bone marrow. Hematopoietic stem-cell transplantation or bone marrow transplantation (BMT) is the treatment of choice for young patients who have a matched sibling donor. Immunosuppression with either anti-thymocyte globulin and cyclosporine or high-dose cyclophosphamide is an effective therapy for patients who are not suitable BMT candidates owing to age or lack of a suitable donor. Results of BMT from unrelated and mismatched donors are improving, but presently this treatment option is best reserved for those patients who do not respond, relapse or develop secondary clonal disorders following immunosuppressive therapy. Efforts are currently underway to both improve immunosuppressive regimens and to expand the application of BMT.

AB - Acquired aplastic anemia is a potentially fatal bone marrow failure disorder that is characterized by pancytopenia and a hypocellular bone marrow. Hematopoietic stem-cell transplantation or bone marrow transplantation (BMT) is the treatment of choice for young patients who have a matched sibling donor. Immunosuppression with either anti-thymocyte globulin and cyclosporine or high-dose cyclophosphamide is an effective therapy for patients who are not suitable BMT candidates owing to age or lack of a suitable donor. Results of BMT from unrelated and mismatched donors are improving, but presently this treatment option is best reserved for those patients who do not respond, relapse or develop secondary clonal disorders following immunosuppressive therapy. Efforts are currently underway to both improve immunosuppressive regimens and to expand the application of BMT.

KW - anti-thymocyte globulin

KW - aplastic anemia

KW - bone marrow failure

KW - bone marrow transplantation

KW - cyclosporine

KW - hematopoietic stem-cell transplantation

KW - high-dose cyclophosphamide

KW - paroxysmal nocturnal hemoglobinuria

UR - http://www.scopus.com/inward/record.url?scp=79955068933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955068933&partnerID=8YFLogxK

U2 - 10.1586/ehm.11.11

DO - 10.1586/ehm.11.11

M3 - Article

C2 - 21495931

AN - SCOPUS:79955068933

VL - 4

SP - 221

EP - 230

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 2

ER -